Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print      Mail a friend       Annual reports

Tuesday 27 May, 2008

Oxford Biomedica PLC

FBR Capital Markets Spring In

RNS Number : 2795V
Oxford Biomedica PLC
27 May 2008
 

 

 

FOR IMMEDIATE RELEASE

27 MAY 2008


OXFORD BIOMEDICA TO PRESENT AT FBR CAPITAL MARKETS SPRING INVESTOR CONFERENCE


Oxford, UK - 27 May 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Dr Mike McDonald, the Company's Chief Medical Officer, will present a company update on Wednesday28 May 2008 at 10.30 am EDT (3.30 pm BST) at the FBR Capital Markets 12th Annual Spring Investor Conference at the Grand Hyatt New York in New York. The presentation will be webcast live and may be accessed under the investors section of the Company's website, www.oxfordbiomedica.co.uk. The presentation webcast will also be available for replay.

-Ends-


For further information, please contact:


Oxford BioMedica plc: 

Professor Alan Kingsman, Chief Executive


Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson


Tel: +44 (0)20 7588 2828

City/Financial Enquiries:

Lisa BaderoonMark Court/ Mary-Jane Johnson Buchanan Communications


Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:

Holly Griffiths/ Katja Stout/ Claire Mosley

College Hill Life Sciences


Tel: +44 (0)20 7457 2020

US Enquiries:

Thomas Fechtner

The Trout Group LLC


Tel: (646) 378 2900


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 


The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, a therapeutic vaccine for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's diseasein a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, WyethSigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. 


Further information is available at www.oxfordbiomedica.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGCGDUSDDGGIR